| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8962189 | Lung Cancer | 2018 | 7 Pages |
Abstract
At the current marketed price, first-line osimertinib therapy in patients with advanced EGFR-mutant lung adenocarcinoma is not cost-effective in Canada. Reduction of osimertinib cost, for example by 25%, can significantly improve the cost-effectiveness profile.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Doreen A. Ezeife, Veronica Kirk, Derek S. Chew, Nancy A. Nixon, Roy Lee, Lisa W. Le, Kelvin K.-W. Chan, Natasha B. Leighl,